Rubedo Life Sciences
develops selective senolytics using its AI-driven ALEMBIC platform; its lead candidate RLS-1496, a topical GPX4 modulator, reported positive preliminary Phase 1 results in plaque psoriasis, atopic dermatitis and skin aging.
- Country
- United States
senolytic
dermatology
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Geroscience & senolytics | regenerative-personalized | High | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.